uniQure (QURE)

• Market cap: $794M
• 1 day: -2.49%
• 5 days: -17.27%
• 1 month: -7.6%
• 3 months: -4.24%
• 6 months: -0.41%
• Year to date: -19.83%
• 1 year: 167.47%
• 5 years: -65.75%
• 10 years: -49.84%
• Sector: Healthcare
• Industry: Biotechnology

About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Employees: 209

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

325% more call options, than puts

Call options by funds: $81.3M | Put options by funds: $19.1M

39% more capital invested

Capital invested by funds: $532M [Q1] → $738M (+$206M) [Q2]

10% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 29

4.25% more ownership

Funds ownership: 92.46% [Q1] → 96.71% (+4.25%) [Q2]

2% more funds holding

Funds holding: 140 [Q1] → 143 (+3) [Q2]

8% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 48

33% less funds holding in top 10

Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $35
• Avg. target: $53
• High target: $70

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick R. Trucchio	$70	Buy Reiterated	8 Sep 2025
Chardan Capital Daniil Gataulin	$35	Buy Maintained	8 Sep 2025